News
MBIO
--
0.00%
--
Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
WORCESTER, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematolog...
GlobeNewswire · 2d ago
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologi...
GlobeNewswire · 02/26 13:00
Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mustang Bio, Inc...
Simply Wall St. · 02/15 06:39
Cell therapy biotech Vor Biopharma prices upsized IPO at $18/share, trades today
Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range
Seekingalpha · 02/05 11:58
Oppenheimer Issues a Buy Rating on Mustang Bio (MBIO)
In a report released yesterday, Mark Breidenbach from Oppenheimer assigned a Buy rating to Mustang Bio (MBIO), with a price target of $13.00. The
SmarterAnalyst · 02/03 01:15
BRIEF-Mustang Bio Provides Updates On Its Lentiviral Gene Therapies For The Treatment Of X-Linked Severe Combined Immunodeficiency
reuters.com · 02/02 12:35
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy WORCESTE...
GlobeNewswire · 02/02 12:30
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy WORCESTE...
GlobeNewswire · 02/02 12:30
The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25)
Benzinga · 01/26 13:07
ATOS, EXPR, SOL and UAVS among midday movers
Gainers: Aemetis (AMTX) +105%.Express (EXPR) +98%.MingZhu Logistics (YGMZ) +50%.TS Innovation Acquisitions (TSIA) +45%.IZEA Worldwide (IZEA) +43%.Orbital Energy (OEG) +36%.VYNE Therapeutics (VYNE) +35%.Accelerate Diagnostics (AXDX) +35%.Atossa Therapeutics...
Seekingalpha · 01/25 17:48
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 01/21 13:05
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, t...
GlobeNewswire · 01/05 13:30
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, t...
GlobeNewswire · 01/05 13:30
These 2 Penny Stocks Are Poised for a Massive Rally, Say Analysts
The conventional wisdom is that we’re on the cusp of another major stock market rally. 2020 has been a volatile year, with the unprecedented ‘coronavirus recession’ in February and March, followed by a bull run through the summer and fall, with increased v...
TipRanks · 12/22/2020 18:17
These 2 Penny Stocks Are Poised for a Massive Rally, Say Analysts
The conventional wisdom is that we’re on the cusp of another major stock market rally. 2020 has been a volatile year, with the unprecedented ‘coronavirus recession’ in February and March, followed by a bull run through the summer and fall, with increased v...
TipRanks · 12/22/2020 18:17
These 2 Penny Stocks Are Poised for a Massive Rally, Say Analysts
TipRanks · 12/22/2020 18:17
Mustang Bio launches early-stage CAR T therapy study in brain tumor
Mustang Bio ([[MBIO]] +5.7%) has initiated Phase 1 single-center, two-arm clinical trial evaluating MB-101 (autologous IL13Rα2-CAR T cells) in leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma).The 30-subject trial will establish the safety
Seekingalpha · 12/21/2020 20:44
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13R2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
GlobeNewswire · 12/21/2020 13:00
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, a...
GlobeNewswire · 12/21/2020 13:00
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, a...
GlobeNewswire · 12/21/2020 13:00
Webull provides a variety of real-time MBIO stock news. You can receive the latest news about Mustang Bio through multiple platforms. This information may help you make smarter investment decisions.
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).